secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOGEN INC. (BIIB)
CIK:        0000875045
Form:       8-K
Filed at:   2022-07-20T23:59:59+00:00
Accession:  0000875045-22-000020
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biogen Q2 revenue $2.59B, GAAP EPS $7.24; raises full-year guidance
-------------------------------------------------------------------

- Q2 total revenue $2,589M, down 7% YoY; MS revenue $1,719M (-4%), SPINRAZA $431M (-14%).
- GAAP diluted EPS $7.24; Non-GAAP diluted EPS $5.25.
- FDA granted Priority Review for lecanemab (Alzheimer's) with decision by Jan 6, 2023; Phase 3 data expected Fall 2022.
- Second positive Phase 3 for zuranolone in PPD; joint U.S. filing for MDD and PPD expected H2 2022.
- Launched BYOOVIZ (biosimilar Lucentis) in U.S.; raised full year 2022 financial guidance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875045/000087504522000020/0000875045-22-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875045/000087504522000020/biib-20220720.htm
  HTML page:      https://secwatch.observer/filing/0000875045-22-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer